Healthcare Providers and Services
Company Overview of AlloSource, Inc.
AlloSource, Inc. operates as a tissue bank that develops, processes, and distributes standard and customized precision allograft products to the medical community in the United States and internationally. The company offers precise bone, skin, soft-tissue, and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures. It provides osteobiologic grafts, including AlloStem, cellular bone allograft for general bone grafting applications; AlloFuse DBM that includes gel, paste, and putty bone graft substitutes; and AlloFlex, a cancellous bone allograft. The company also offers cancellous and structural general orthopedic grafts; spinal grafts, including ce...
6278 South Troy Circle
Centennial, CO 80111
Founded in 1994
Key Executives for AlloSource, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President
Vice President of Operations
General Counsel and Vice President of Corporate Compliance
Chairman of Medical Advisory Board and Senior Medical Director
Compensation as of Fiscal Year 2015.
AlloSource, Inc. Key Developments
AlloSource Announces Positive Clinical Results for the Use of Alloskin
Aug 6 15
AlloSource announced positive clinical results for the use of AlloSkin to help heal diabetic foot ulcers, venous leg ulcers or surgical/traumatic wounds. The peer-reviewed, retrospective study, "Human Skin Allograft for Patients with Diabetic Foot Ulcers, Venous Leg Ulcers, or Surgical/Traumatic Wounds: A Retrospective, Descriptive Study," was conducted at wound clinics in the Inova Health System and published in Ostomy Wound Management. Dr. Eric Desman was the principal investigator for this study, which included 36 patients and is the first identified study of very large chronic wounds treated with human skin allografts. The mean wound size in the study was 19.4 cm2. The study was conducted among outpatients with non-healing diabetic foot ulcers, venous leg ulcers and surgical or traumatic wounds managed with AlloSkin, a meshed, partial-thickness, cryopreserved human skin allograft. The study results showed patient healing rates of 47% at 12 weeks and 58% at 20 weeks, which is favorable in comparison to the healing rates of living cell-based skin substitutes, especially considering the large wound size in the study.
AlloSource Appoints Kerr Holbrook as Chief Commercial Officer
May 14 15
AlloSource announced the appointment of Kerr Holbrook as Chief Commercial Officer. Holbrook has more than 25 years of experience in a variety of sales, marketing and business development positions for healthcare service and manufacturing companies. He also has extensive experience bringing products to market, including collaborating with research and development, creating commercialization plans and managing their implementation. Most recently, he served as Group Vice President of Strategy, Portfolio Management and Business Development for Covidien in Boulder, Colorado. As Chief Commercial Officer, Holbrook will oversee AlloSource's commercialization strategy and organization, including distribution channels and customer service, both domestic and international. He will work closely with all departments in the organization to drive strategic partnerships and prioritize growth opportunities.
AlloSource Launches of AlloSkin AC
Apr 29 15
AlloSource announced the launch of AlloSkin AC, an acellular dermal allograft. The Centers for Medicare & Medicaid Services (CMS) also moved AlloSkin RT, a meshed human dermal graft, from the low-cost to the high-cost category for reimbursement. AlloSkin AC is a decellularized, meshed, dermis-only skin allograft. The resulting acellular matrix is a favorable microenvironment for bio-ingrowth, acting as a scaffold onto which the body can build dermal tissue through revascularization and cellular repopulation. Acellular dermal tissue is used clinically in the treatment of partial and full-thickness burns, traumatic tissue loss due to injury and for chronic wounds such as pressure ulcers, diabetic foot ulcers and venous and arterial ulcers. AlloSkin AC has Outpatient Medicare reimbursement coverage under the Novitas Administrative Contract. AlloSkin RT has broad clinical applications for acute and chronic wound therapy and is a ready-to-use, shelf-stable graft with room temperature storage. CMS' new high-cost category coverage for AlloSkin RT is a result of new regulations in 2014 for skin substitutes, which are divided into high- and low-cost categories for bundled product and application payment within Hospital Outpatient Departments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|